<DOC>
	<DOCNO>NCT01268774</DOCNO>
	<brief_summary>Patients multiple myeloma see survival rate strongly improve use new anti angiogenic agent . Among , new chemotherapy thalidomide lenalinomide frequently successfully suggest therapeutic protocol MPT however strongly increase risk venous thrombo embolic disease ( DVT PTE ) 20 % . In condition , prevention risk propose physician either low molecular weight heparin ( LMWH ) anticoagulants antiplatelets agent . Pending new recommendation management VTED , purpose study describe real life condition management oncologists thrombo embolic risk patient</brief_summary>
	<brief_title>Preventive Treatment VETD Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide Lenalinomide .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients multiple myeloma receive chemotherapy protocol include thalidomide lenalidomide Patients involve interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>